n-acylethanolamines

PDP-EA is an activator of fatty acid amide hydrolase(FAAH) and enhances the amidohydrolase activity of FAAH.

LEI-401 is a selective and potent NAPE-PLD inhibitor that crosses the blood-brain barrier (IC50: 27 nM).LEI-401 reduces the level of n-acylethanolamines (NAEs) in the brain of free-ranging mice and modulates their emotional behaviour.

Linoleoyl ethanolamide phosphate is an intermediate in the biosynthesis of linoleoyl ethanolamide, generated through phospholipase C-mediated hydrolysis of N-acylphosphatidylethanolamine. Linoleoyl ethanolamide phosphate, along with other endogenous N-acylethanolamines, is thought to regulate food intake by selectively prolonging feeding latency and post-meal interval [Linoleoyl Ethanolamide Phosphate].

Pentadecanoyl ethanolamide, a derivative of the endogenous lipid amides (N-acylethanolamines), demonstrates anticonvulsant efficacy in electroshock-induced seizures in mice, exhibiting minimal toxicity [1].

Palmitoleoyl Ethanolamide (POEA) is an endogenous fatty acid ethanolamide (FAE) and a member of the endocannabinoid-like family of molecules. It is a derivative of the monounsaturated fatty acid palmitoleic acid. Similar to the well-studied palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), POEA is thought to exert biological effects by modulating peroxisome proliferator-activated receptor α (PPAR-α), G protein-coupled receptors (e.g., GPR119), or through the "entourage effect" by modulating endocannabinoid signaling. It has demonstrated potential activities in anti-inflammation, analgesia, and metabolic regulation.